10-Q: Notable Labs Reports First Quarter 2024 Financial Results, Cites Cash Concerns

Sentiment:

Quarterly Report 15 May 2024 4:05 PM

Notable Labs reports its Q1 2024 financial results, highlighting a net loss and expressing concerns about its ability to continue as a going concern without additional funding.

Capital raiseThe company states that its ability to fund its operations will require additional capital.The company intends to raise such capital through the issuance of additional debt or equity, including through licensing or collaboration agreements.The company states that if such financing is not approved, does not occur, or alternative financing is not available at adequate levels or on acceptable terms, or profitable operations are not attained, the Company could be required to significantly reduce operating expenses and delay, reduce the scope of or eliminate some of its development programs, enter into a collaboration or other similar arrangement with respect to commercialization rights to any of its product candidates, out license intellectual property rights to its product candidates and sell unsecured assets, or a combination of the above.

Worse than expectedThe company reported a net loss of $3.8 million for the quarter.The company's cash reserves are limited, raising concerns about its ability to continue as a going concern.The company's auditors have raised substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.

Summary

Notable Labs, a clinical-stage platform therapeutics company, reported its financial results for the first quarter ended March 31, 2024.
The company has incurred losses and negative cash flows since its inception, with an accumulated deficit of approximately $86.1 million as of March 31, 2024.
Cash reserves stood at $8.2 million as of March 31, 2024, and the company forecasts cash needs in excess of current liquidity.
Notable Labs is developing predictive precision medicines for cancer patients through its Predictive Precision Medicines Platform (PPMP).
The company expects to initiate a Phase 2 trial evaluating Volasertib in adult AML in the second quarter of 2024, with initial results expected in the fourth quarter of 2024.
Notable Labs is co-developing Fosciclopirox with CicloMed LLC for AML patients.
The company's ability to continue as a going concern is dependent on securing additional financing and achieving profitable operations.
For the three months ended March 31, 2024, services revenue was $1 thousand, research and development expenses were $1.6 million, and general and administrative expenses were $2.3 million, resulting in a net loss of $3.8 million.
As of May 9, 2024, Notable has cash and cash equivalents of $6.8 million and management believes Notable will be able to finance its operations through September 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive developments in the clinical pipeline, the financial situation raises significant concerns about the company's ability to continue as a going concern without additional funding.

Positives

Notable Labs is advancing its lead asset, Volasertib, with a Phase 2 trial expected to begin in Q2 2024.
The company is co-developing Fosciclopirox, expanding its pipeline for AML treatment.
Notable Labs' PPMP platform has shown promising results in predicting patient response to treatments.
General and administrative expenses decreased to $2.3 million from $3.9 million for the three months ended March 31, 2024 compared to the three months ended March 31, 2023.

Negatives

Notable Labs has a significant accumulated deficit of $86.1 million.
The company's cash reserves are limited, raising concerns about its ability to continue as a going concern.
Notable Labs has a history of losses and negative cash flows from operations.
The company's auditors have raised substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.

Risks

Notable Labs may need to raise additional funding, which may not be available on acceptable terms or at all.
Failure to obtain necessary capital may force the company to delay, limit, or terminate its product development efforts.
The company is dependent on its technology, and there is no guarantee that its product candidates will receive regulatory approval or be commercialized.
Clinical trials may encounter delays, and the company may fail to demonstrate safety and efficacy to regulatory authorities.
Legislative and regulatory activity may exert downward pressure on potential pricing and reimbursement for product candidates.
The company relies on third parties for manufacturing, protocol development, and clinical testing, which may not perform satisfactorily.
The market price of the company's ordinary shares may be highly volatile.

Future Outlook

Notable Labs expects to continue incurring significant operating losses and needs to secure additional funding to sustain operations. The company plans to advance the clinical development of Volasertib and Fosciclopirox and is seeking additional assets for in-licensing.

Management Comments

Management believes Notable will be able to finance its operations through September 2024 based on its current cash position and planned expense run rate.

Industry Context

Notable Labs operates in the competitive pharmaceutical industry, focusing on precision medicine for cancer treatment. The company's PPMP platform aims to improve patient outcomes by predicting treatment response, differentiating it from traditional biomarker-based approaches.

Comparison to Industry Standards

It is difficult to compare Notable Labs directly to industry standards due to its unique PPMP platform and focus on predictive precision medicine.
However, the company's approach aligns with the broader industry trend towards personalized medicine and targeted therapies.
Companies like Foundation Medicine and Guardant Health are also involved in personalized cancer diagnostics, but their approaches differ from Notable Labs' PPMP platform.
Notable Labs' strategy of in-licensing assets with demonstrated clinical activity but limited patient response is similar to that of other pharmaceutical companies seeking to repurpose or improve existing drugs.

Related Party Transactions

For consulting services with a Board Member, the Company recorded general and administrative expenses of $60,450 and $43,403 for the three months ended March 31, 2024 and 2023.

Stakeholder Impact

Shareholders face potential dilution if the company raises additional capital through equity offerings.
Employees' job security is uncertain due to the company's financial situation and potential need to reduce operating expenses.
Patients may benefit from the development of new precision medicine treatments, but the company's financial challenges could delay or halt these efforts.
Suppliers and creditors face increased risk of non-payment if the company's financial situation worsens.

Next Steps

Initiate Phase 2 trial evaluating Volasertib in adult AML in the second quarter of 2024.
Enroll the first PPMP-predicted responder in the Volasertib trial in the fourth quarter of 2024.
Continue co-development of Fosciclopirox with CicloMed LLC.
Seek additional assets for in-licensing and development.
Secure additional funding through equity, debt, or collaboration agreements.

Key Dates

Date	Description
2000-02-01	Date of the 2000 Plan
2000-02-28	Date of the 2000 Plan
2011-04-01	Date of the 2011 Plan
2011-04-30	Date of the 2011 Plan
2014-09-01	Date of the 2014 Plan
2014-09-30	Date of the 2014 Plan
2015-08-31	Date of the 2015 Plan
2017-12-31	Date of the 2015 Plan
2019-12-31	Date of the 2015 Plan
2021-09-01	Date of the Oncoheroes Safe Agreement
2021-09-30	Date of the Oncoheroes Safe Agreement
2021-10-31	Date of the Oncoheroes Safe Agreement
2022-12-31	Date of the 2015 Plan
2023-03-31	Comparative period end date
2023-10-16	Date of the Merger Agreement
2023-12-31	Prior year end date
2024-01-01	Start of the current reporting period
2024-03-31	End of the current reporting period
2024-04-01	Date of the 2024 Plan
2024-04-30	Date of the 2024 Plan
2024-05-06	Date shares outstanding were calculated
2024-05-08	Date of subsequent events
2024-05-15	Report date

Keywords

Volasertib, Fosciclopirox, PPMP, AML, Clinical Trials, Financial Results, Notable Labs, Going Concern, Funding, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.